Outcomes of patients with COPD before and after initiation of treatment with budesonide/glycopyrrolate/formoterol fumarate: Results from the US ARCTOS study.

Sanjay Sethi¹, Laurence Gozalo², Donna McMorrow², Norbert Feigler³, Amanda Spy³, Sunny Hirpara⁴, Keith Szymanski⁴, Christopher Evangelista³, Joseph Tkacz², Hayley D Germack⁵

¹University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY, United States.

²Inovalon, Bowie, MD, United States.

³US Medical-Respiratory, BioPharmaceuticals Medical, Wilmington, DE, United States.

⁴US Clinical Value and Outcomes, BioPharmaceuticals, Wilmington, DE, United States.

⁵US Evidence, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, United States. Electronic address: Hayley.germack@astrazeneca.com.

PubMed DOI

Abstract

OBJECTIVE: To assess change in COPD exacerbations, healthcare resource utilization, and costs among patients diagnosed with COPD following initiation of budesonide/glycopyrrolate/formoterol fumarate (BGF), a single inhaler triple therapy for COPD. METHODS: This study was a retrospective analysis of the Inovalon MORE2 Registry and 100% Medicare Fee-for-Service claims databases between 1/1/2021-3/3…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.